Related Experiment Video
Updated: May 20, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Mild cognitive impairment in older adults
1Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, AZ, USA. geda.yonas@mayo.edu
Current Psychiatry Reports
|July 10, 2012
Summary
Mild cognitive impairment (MCI) is a high-risk stage for dementia. Identifying preclinical Alzheimer's disease (AD) in asymptomatic individuals using biomarkers and neuroimaging is crucial for future prevention strategies.
Area of Science:
- Neurology
- Gerontology
- Biomarker Research
Background:
- Mild cognitive impairment (MCI) represents a critical intermediate stage between normal aging and dementia.
- Individuals with MCI are at a significantly elevated risk of progressing to dementia.
- Early identification of at-risk individuals is paramount for developing effective prevention strategies.
Purpose of the Study:
- To discuss the significance of MCI as a high-risk group for dementia.
- To highlight the shift towards identifying asymptomatic individuals with underlying Alzheimer's disease (AD) pathology.
- To introduce the new classification scheme for AD by the Alzheimer's Association and NIA.
Main Methods:
- Review of current research trends in cognitive decline and dementia.
- Discussion of biomarker and neuroimaging technologies for detecting AD pathology.
- Explanation of the new NIA-AA research framework for classifying AD stages.
Main Results:
- MCI is a key indicator of increased dementia risk.
- Biomarkers and neuroimaging enable detection of preclinical AD in asymptomatic individuals.
- A new classification system categorizes AD into preclinical, MCI due to AD, and dementia stages.
Conclusions:
- The field is advancing towards early detection of AD pathology before symptomatic stages.
- The new classification scheme provides a framework for research into AD progression.
- Research continues to explore risk factors for non-Alzheimer's dementias.
More Related Videos
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Related Concept Videos
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:29Intellectual Disability
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...